Last reviewed · How we verify
CARCIK-CD19
At a glance
| Generic name | CARCIK-CD19 |
|---|---|
| Sponsor | Fondazione Matilde Tettamanti Menotti De Marchi Onlus |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia (PHASE1, PHASE2)
- Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL (PHASE2)
- Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CARCIK-CD19 CI brief — competitive landscape report
- CARCIK-CD19 updates RSS · CI watch RSS
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus portfolio CI